皮肤科常用药物在哺乳期的合理使用 |
| 杨滨宾，邓丹琪 |
| 昆明医科大学第二附属医院皮肤性病科，云南 昆明 650101 |
Rational use of common dermatologicmedicationsin lactation |
| YANG Bin-bin,DENG Dan-qi |
| Department of Dermatology,The Second Affi liated Hospital of Kunming Medical University,Kunming,Yunnan 650101,China |
| 摘要 |
[目的] 皮肤科医生经常会面临哺乳期妇女提出的有关哺乳期局部用药和全身性用药安全性的问题。哺乳期的安全数据，特别是关于皮肤科特有药物的数据非常有限，查找困难。本文通过回顾有关哺乳期常见皮肤病治疗药物安全性的文献，对皮肤科常用的药物在哺乳期的合理使用进行归纳总结。 |
| 关键词 |
皮肤病药物 ; 哺乳期 ; 药物安全性 |
| Abstract： |
Dermatologists are frequently faced with questions from women who are breastfeeding about the safety of commonly prescribed topicaland systemic medications during lactation. Safety data in lactation, particularly regarding medications that are unique to dermatology, are limited and canbe diffi cult to locate. We have consolidated the available safety data in a single reference guide for clinicians. We reviewed literature pertaining to thesafety of common dermatologic therapies in lactation and summarized therational use of common dermatologic medications in lactation. |
| Keywords |
Dermatologic drugs ; Lactation ; Medication safety |
| 参考文献 |
［1］ Lee S,Kelleher S L.Biological underpinnings of breastfeeding chal-lenges:the role of genetics,diet,and environment on lactation physiol-ogy[J].Am J PhysiolEndocrinolMetab,2016,311(2):E405-422.
［2］ Elliott A B,Chakravarty E F.Immunosuppressive medications duringpregnancy and lactation in women with autoimmune diseases[J].Womens Health(Lond),2010,6(3):431-440.
［3］ Casey T M,Plaut K.The role of glucocorticoids in secretory activationand milk secretion,a historical perspective[J].J Mammary Gland BiolNeoplasia,2007,12(4):293-304.
［4］ Hollanders J J,Heijboer A C,Finken M J J.Nutritional programming byglucocorticoids in breast milk:Targets,mechanisms and possible impli-cations[J].Best Pract Res Clin Endocrinol Metab,2017,31(4):397-408.
［5］ Ogburn T,Philipp B L,Espindola D.Assessment of breastfeeding in-formation in general obstetrics and gynecology textbooks[J].J HumLact,2011,27(1):58-62.
［6］ Gomez-Lobo V,Landy H J,Fishbein T M.Pregnancy in an intestinaltransplant recipient[J].Obstet Gynecol,2012,120(2Pt2):497-500.
［7］ American Academy of Pediatrics Committee on D.Transfer ofdrugs and other chemicals into human milk[J].Pediatrics,2001,108(3):776-789.
［8］ Temprano K K,Bandlamudi R,Moore T L.Antirheumatic drugs in preg-nancy and lactation[J].Semin Arthritis Rheum,2005,35(2):112-121.
［9］ Edstein M D,Veenendaal J R,Hyslop R.Excretion of chloroquine,dap-sone and pyrimethamine in human milk[J].Br J ClinPharma-co,1986,22(6):733-235.
［10］ Sanders S W,Zone J J,Rollins D E.Hemolytic anemia induced bydapsone transmitted through breast milk[J].Ann Intern Med,1982,96(4):465-466.
［11］ Bertino E,Varalda A,Di N P,et al.Drugs and breastfeeding:instruc-tions for use Medications in pregnancy and lactation:Part 2.Drugswith minimal or unknown human teratogenic effect[J].J Matern FetalNeonatal Med,2012,25 Suppl 4(2Pt1):78-80.
［12］ Cozzani E,Cioni M,Parodi A.The management of autoimmune dis-eases in preconception,pregnancy and lactation[J].G Ital Dermatol-Venereol,2019,154(3):299-304.
［13］ Carina G S,Maria H,Angela T,et al.The EULAR points to considerfor use of antirheumatic drugs before pregnancy,and during pregnan-cy an d lactation[J].Ann Rheum Dis,2016,75(5):795-810.
［14］ Moretti M E,Sgro M,Johnson D W,et al.Cyclosporine excretion intobreast milk[J].Transplantation,2003,75(12):2144-2156.
［15］ Gisbert J P.Safety of immunomodulators and biologics for thetreatment of inflammatory bowel disease during pregnancy andbreast-feeding[J].Infl amm Bowel Dis,2010,16(5):881-895.
［16］ Zheng S,Easterling T R,Hays K,et al.Tacrolimus placental transfer atdelivery and neonatal exposure through breast milk[J].Br J ClinPhar-macol,2013,76(6):988-996.
［17］ Gromnica-Ihle E,Krüger K.Use of methotrexate in young pa-tients with respect to the reproductive system[J].ClinExpRheuma-tol,2010,28(5 Suppl 61):80-84.
［18］ Moretti M E,Verjee Z,Ito S,et al.Breast-feeding during maternal useof azathioprine[J].Ann Pharmacother,2006,40(12):2269-2272.
［19］ Gardiner S J,Gearry R B,Begg E J.Exposure to thiopurine drugsthrough breast milk is low based on metabolite concentrations inmother-infant pairs[J].Br J ClinPharmacol,2006,62(4):453-456.
［20］ Christensen L A,Dahlerup J F,Schmiegelow K.Azathioprine treatmentduring lactation[J].Aliment PharmacolTher,2008,28(10):1209-1213.
［21］ Grunewald S,Jank A.New systemic agents in dermatology with respectto fertility,pregnancy,and lactation[J].J DtschDermatolGes,2015,13(4):277-289.
［22］ Fritzsche J,Pilch A,Weber-Schoendorfer C.Infliximab and adali-mumab use during breastfeeding[J].J ClinGastroenterol,2012,46(8):718-219.
［23］ Kane S,Ford J,Cohen R,et al.Absence of infliximab in infants andbreast milk from nursing mothers receiving therapy for Crohn’s d is-ease before and after delivery[J].J ClinGastroenterol,2009,43(7):613-616.
［24］ Murashima A,Watanabe N,Yamaguchi K.Etanercept during pregnan-cy and lactation in a patient with rheumatoid arthritis:drug levels inmate rnal serum,cord blood,breast milk and the infant’s serum[J].AnnRheum Dis,2009,68(11):1793-1804.
［25］ Berthelsen B G,Nielsen C T,Hellmuth E.Etanercept concentra-tions in maternal serum,umbilical cord serum,breast milk and childserum during breastfeeding[J].Rheumatology (Oxford),2010,49(11):2225-2237.
［26］ Yarur A,Kane S V.Update on pregnancy and breastfeeding in the eraof biologics[J].Dig Liver Dis,2013,45(10):787-794.
［27］ Ito S,Blajchman A,Koren G.Prospective follow-up of adverse reac-tions in breast-fed infants exposed to maternal medication[J].Am JObstet Gynecol,1993,168(5):1393-1399.
［28］ Chow C K,Koren G.Sedating drugs and breastfeeding[J].Can FamPhysician,2015,61(3):241-253.
［29］ Saito J,Yakuwa N,Suzuki T,et al.Ebastine during pregnancy andlactation in a patient with chronic urticaria:ebastine and carebastinelevels in maternal serum,cord blood,breast milk,and the infant’s se-rum[J].J EurAcadDermatolVenereol,2020,150(4):156-166.
［30］ Benyamini L,Merlob P,Bulkowstein M,et al.The safety of amoxi-cillin/clavulanic acid and cefuroxime during lactation[J].Ther DrugMonit,2005,27(4):499-502.
［31］ Van W J J,Leferink T M,Ter H P G J.Antibiotics and lactation:Anoverview of relative infant doses and a systematic assessment ofclinical studies[J].Basic Clin Pharmacol Toxico,2019,124(1):5-17.
［32］ Force R W.Fluconazole concentrations in breast milk[J].Pediatr In-fect Dis J,1995,14(3):235-246.
［33］ Chen S,Sun K Y,Ran Y P.Effi cacy and safety of itraconazole use ininfants[J].World J Pediatr,2016,12(4):399-407.
［34］ Brown S M,Aljefri K,Hampton P.Systemic medications used intreatment of common dermatological conditions:safety profi le withrespect to pregnancy,breast feeding and content in seminal fl uid[J].Dermatolog Treat J,2019,30(1):2-18.
［35］ Drake A L,Roxby A C,John-Stewart G,et al.Infant safety during andafter maternal valacyclovir therapy in conjunction with antiretroviralHIV-1 prophylaxis in a randomized clinical trial[J].PLoS One,2012,7(4):228-234.
［36］ Bork K,Benes P.Concentration and kinetic studies of intravenousacyclovir in serum and breast milk of a patient with eczema herpeti-cum[J].J Am AcadDermatol,1995,32(6):1053-1055.
［37］ Fujimori K,Kyozuka H.Drugs in pregnancy and lactation[J].NihonRinsho,2012(70):330-340.
［38］ Kulski J K,Hartmann P E.Changes in the concentration of cortisolin milk during different stages of human lactation[J].Aust J ExpBiolMed Sci,1981,59(Pt 6):769-778.
［39］ Westermann L,Weichenthal M,Glser R,et al.Glucocorticosteroid-re-sistant pemphigoid gestationis:successful treatment with adjuvantimmunoadsorption[J].J Dermatol,2012,39(2):168-171.
［40］ De S P,Bongo I G,Severi F.Factitious hypertension with mineralocor-ticoid excess in an infant[J].Helv Paediatr Acta,1983,38(2):185-193.
［41］ Gouraud A,Bernard N,Descotes J,et al.Follow-up of tacrolimusbreastfed babies[J].Transplantation,2012,94(6):38-40.
［42］ Coscia L A,Constantinescu S,Moritz M J.The 25th Anniversary ofthe National Transplantation Pregnancy Registry[J].ClinTransp,2015(31):57-68.
［43］ Franssen M E,van d W G J,Arnold W P.A retrospective study of theteratogenicity of dermatological coal tar products[J].ActaDermVene-reol,1999,79(5):390-391.
［44］ Scheepers P T,van H J L,van d V P G.Uptake of pyrene in a breast-fedchild of a mother treated with coal tar[J].PediatrDermatol,2009,26(2):184-187.
［45］ Nguyen M,Boutignon H,Jehan F,et al.Infantile hypercalcemia andhypercalciuria:new insights into a vitamin D-dependent mechanismand res ponse to ketoconazole treatment[J].J Pediatr,2010,157(2):296-302.
［46］ Roos T C,Alam M,Bickers D R.Pharmacotherapy of ectoparasiticin-fections[J].Drugs,2001,61(8):1067-1088.
［47］ Du J,Gridneva Z,Hartmann P E,et al.Longitudinal study of pesti-cide residue levels in human milk from Western Australia during 12months of lactation:Exposure assessment for infants[J].Sci Rep,2016,6(3):48-55.
［48］ Wananukul S,Chatproedprai S,Wananukul W.Clinical response andsafety of malathion shampoo for treatment of head lice in a primaryschool[J].J Med Assoc Thai,2011,94(4):465-469.
|
| 全文稿件 |
皮肤科常用药物在哺乳期的合理使用.pdf (1326KB)
|
|
阅读: 241
下载: 161
上传: 2021-09-30 23:45:22
页面: 486
|
|
